Why carry out this study?

In the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis, nintedanib slowed the rate of decline in forced vital capacity (FVC; mL/year) over 52 weeks compared with placebo

We investigated whether the effect of nintedanib on slowing the rate of decline in FVC was consistent across subgroups based on characteristics at baseline of the INBUILD trial

What was learned from the study?

No heterogeneity was detected in the effect of nintedanib on reducing the rate of decline in FVC across subgroups based on demographics, severity of interstitial lung disease, use of anti-acid therapy or use of disease-modifying antirheumatic drugs at baseline

These data support the use of nintedanib as a treatment for progressive pulmonary fibrosis